South San Francisco, CA

November 13, 2024

Opna Bio Announces 2024 ASH Presentations Highlighting Interim Data from Phase 1 Combo Study of BET Inhibitor OPN-2853 with Ruxolitinib in Myelofibrosis, and Promising Preclinical Data with EP300/CBP Bromodomain Inhibitor OPN-6602 in Multiple Myeloma

Opna Announces ASH abstracts 2024

August 26, 2024

South San Francisco, CA

Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor

Appoints Axel Bolte, MBA, MSc to Board Director and Stephanie Oestreich, PhD, MPA to Board Observer

November 21, 2022

Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program and Diversified Pipeline of Clinical and Preclinical Programs

Broad Drug Portfolio Targets Fragile-X Mental Retardation Protein (FMRP) in Cancer, Bromo and Extra Terminal (BET) Domain Proteins, Colony-stimulating Factor 1 Receptor (CSF1R), and Additional Cancer Drivers.

Seminal Research on FMRP’s Emerging Role in Cancer Published in Science.

About Opna Bio

Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X multifunctional RNA-binding protein (FMRP) and a diversified pipeline of validated oncology assets acquired from Plexxikon. The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market.